Supplementary

Table S1 Subsequent therapy

Treatment	Anlotinib (n=20), n (%)	Topotecan (n=26), n (%)
Subsequent therapy	11 (55.0)	19 (73.1)
Chemotherapy	11 (55.0)	13 (50.0)
Radiotherapy	3 (15.0)	2 (7.7)
Immunotherapy	3 (15.0)	2 (7.7)
Targeted therapy	2 (10.0)	13 (50.0)
Anlotinib	1 (5.0)	12 (46.2)
Other	1 (5.0)	1 (3.8)

https://dx.doi.org/10.21037/tlcr-24-274

Table S2 Adverse events

Adverse event	Anlotinib (n=20), n (%)		Topotecan (n=26), n (%)	
	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4
Hypertension	2 (10.0)	1 (5.0)	0 (0.0)	0 (0.0)
Weight loss	4 (20.0)	0 (0.0)	8 (30.8)	0 (0.0)
Anorexia	2 (10.0)	0 (0.0)	12 (46.2)	2 (7.7)
Vomiting	1 (5.0)	0 (0.0)	4 (15.4)	0 (0.0)
Diarrhea	0 (0.0)	1 (5.0)	6 (23.1)	5 (19.2)
Abdominal pain	1 (5.0)	0 (0.0)	2 (7.7)	1 (3.8)
Constipation	0 (0.0)	0 (0.0)	2 (7.7)	0 (0.0)
Fatigue	5 (25.0)	0 (0.0)	13 (50.0)	5 (19.2)
Hemoptysis	1 (5.0)	2 (10.0)	3 (11.5)	0 (0.0)
Rash	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hand and foot skin reaction	1 (5.0)	1 (5.0)	4 (15.4)	1 (3.8)
Limb pain	1 (5.0)	1 (5.0)	0 (0.0)	0 (0.0)
Anemia	4 (20.0)	0 (0.0)	9 (34.6)	2 (7.7)
Leukocytopenia	2 (10.0)	1 (5.0)	8 (30.8)	6 (23.1)
Neutropenia	2 (10.0)	0 (0.0)	7 (26.9)	7 (26.9)
Lymphopenia	2 (10.0)	0 (0.0)	8 (30.8)	1 (3.8)
Thrombocytopenia	1 (5.0)	1 (5.0)	2 (7.7)	3 (11.5)
Febrile neutropenia	0 (0.0)	0 (0.0)	1 (3.8)	2 (7.7)
Hypothyroidism	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
Proteinuria	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
Urine erythrocyte	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Urine leukocyte	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
AST increase	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)
ALT increase	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
GGT elevation	1 (5.0)	0 (0.0)	1 (3.8)	0 (0.0)
Conjugated bilirubin increase	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypercholesteremia	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hyponatremia	0 (0.0)	0 (0.0)	4 (15.4)	2 (7.7)
Hypochloridemia	0 (0.0)	0 (0.0)	3 (11.5)	0 (0.0)
Hypocalcemia	0 (0.0)	0 (0.0)	2 (7.7)	0 (0.0)
Hyperglycemia	1 (5.0)	0 (0.0)	2 (7.7)	0 (0.0)

AST, aspartate transaminase; ALT, alanine aminotransferase; GGT, glutamyl transpeptidase.

https://dx.doi.org/10.21037/tlcr-24-274